The National Institute of Neurological Disorders and Stroke (NINDS) requests small business innovation research (SBIR) applications for countermeasures against chemical threats (CounterACT) therapeutics development. This announcement is made together with 5 other components of the National Institutes of Health (NIH).*
The increased risk of a terrorist attack in the
Areas of research interest include, but are not limited to: therapies based on acute toxicity of the chemical threat agent; therapies based on sequestration or inactivation of the chemical agent in vivo, such as stoichiometric scavengers or cyanide sulfur donors; alternate routes of administration for new or approved therapies that are safe, effective, and easy to administer during a mass casualty scenario; toxicokinetic and route of administration studies with threat agents for the purpose of developing better medical countermeasures; re-evaluation of supportive measures and other medical approaches to delay mortality and morbidity until transportation to medical facilities; identification of segments of the general population that are more sensitive to chemical threats; safe and effective therapies for pediatric and elderly segments of the civilian population or for those individuals with pre-existing medical conditions; and medical prophylactic and protective measures appropriate for first responders or other personnel who must enter a contaminated site.
LETTERS OF INTENT RECEIPT DATE:
APPLICATION RECEIPT DATE:
For more information, potential applicants should contact Dr. David Jett, Program Director, Technology Development Group,
NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2177, Bethesda, MD 20892; telephone:
301-496-6035; fax: 301-402-1501; e-mail: email@example.com.
*For a full list of supporting NIH components and a more detailed description of this request for applications, please visit the NIH web site at: http://grants2.nih.gov/grants/guide/rfa-files/RFA-NS-06-006.html.